Filing Flows › Ironwood Pharmaceuticals (IRWD) › Q2 2026 › vs Q2 2025
Ironwood Pharmaceuticals (IRWD) Q2 2026 vs Q2 2025 (year over year)
Ironwood Pharmaceuticals's revenue rose $27.8M (+33%) from $85.2M in Q2 2025 to $113M in Q2 2026. Operating margin 70.2% against 53.2% (+17.0 pts).
Ironwood Pharmaceuticals, Q2 2026: revenue $113M (+33% year over year), operating margin 70.2%, net earnings $51.3M, operating cash flow $58.3M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 70.2% | 53.2% | +17.0 pts |
| Net margin | 45.4% | 27.7% | +17.7 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $113M | $85.2M | $27.8M | +33% |
| Operating profit | $79.3M | $45.3M | $34.0M | +75% |
| Costs & expenses | $33.7M | $39.9M | −$6.2M | -15% |
| Pre-tax earnings | $73.7M | $37.8M | $35.9M | +95% |
| Other expense, net | $5.6M | $7.5M | −$1.9M | -26% |
| Net earnings | $51.3M | $23.6M | $27.7M | +117% |
| Income tax | $22.4M | $14.2M | $8.2M | +58% |
| Depreciation | $457K | $467K | −$10K | -2% |
| Share-based compensation | $3.2M | $4.5M | −$1.3M | -28% |
| Working capital & other | $3.3M | −$43.7M | $47.0M | — |
| Operating cash flow | $58.3M | −$15.1M | $73.3M | — |
Questions
How much did Ironwood Pharmaceuticals's revenue grow year over year in Q2 2026?
Ironwood Pharmaceuticals's revenue rose $27.8M (+33%) from $85.2M in Q2 2025 to $113M in Q2 2026. Operating margin 70.2% against 53.2% (+17.0 pts).